Targeted beta therapy (TBT) represents a promising avenue in cancer treatment. It focuses on utilising radioactive beta-emitting isotopes to destroy cancer cells while minimising damage to surrounding healthy tissue. This sophisticated approach is part of a broader category known as radiopharmaceuticals, which combine radioactive substances with targeting molecules that specifically seek out and bind to cancer cells.
The principle behind TBT hinges on the ability of the targeting molecules, such as antibodies or peptides, to recognise and attach to specific markers or antigens expressed predominantly on the surface of cancer cells. Once the targeting molecule has bound to a cancer cell, the radioactive beta emitter can deliver a lethal dose of radiation directly to the cell, effectively killing it. This targeted approach helps to preserve healthy cells, potentially reducing the side effects commonly associated with more conventional forms of cancer therapy, such as chemotherapy and external beam radiation.
One of the key advantages of TBT is its ability to treat microscopic tumour deposits that may be undetectable with current imaging technologies but are critical to managing metastatic cancers. Additionally, beta radiation has a relatively short penetration range in biological tissues, which allows it to deliver high doses of radiation to the tumour with limited collateral damage.
Research and clinical trials for TBT have been expanding, focusing on various cancers such as prostate, brain, and ovarian cancers. Lutetium-177 and Yttrium-90 are among the most commonly used isotopes in these therapies. These isotopes have been shown to effectively reduce tumour size and improve patients’ survival rates and quality of life.
However, integrating TBT into standard cancer treatment protocols involves overcoming several challenges. The production of radiopharmaceuticals requires sophisticated and expensive facilities. Moreover, the precision in targeting and radiation dose calculations necessitates advanced imaging and dosimetry capabilities, which are not universally available.
Furthermore, as with any treatment involving radiation, there are risks of radiation exposure to non-targeted tissues, which can lead to side effects such as bone marrow suppression. Researchers are continually working to refine targeting mechanisms and improve isotopes to enhance the efficacy and safety of TBT.
In conclusion, targeted beta therapy is a cutting-edge treatment that embodies the shift towards more personalised and precise cancer care. It offers a hopeful future for many patients, particularly those with intractable and metastatic cancers, by potentially providing a more effective and less harmful treatment alternative compared to traditional therapies. The ongoing developments in this field highlight the dynamic nature of cancer treatment research and the continual quest for therapies that can offer better outcomes for patients afflicted with this complex disease.
You are here:
home »
By
| 7 minutes of readingFind out how radiotheranostics medicine is transforming cancer therapy by merging diagnostics with targeted radionuclide therapy.
By
| 14 minutes of readingRadiotheranostics and radiotherapeutics cancer treatments provide personalised care by combining diagnosis and targeted therapy.
Radiotheranostics and Radiotherapeutics in Cancer Diagnosis and Treatment Read Article »
By
| 10 minutes of readingBeta particle emitting radionuclides are utilised in therapeutic nuclear medicine for precise tumour targeting and improved treatment outcomes.
Selected Beta Particle Emitting Radionuclides for Therapeutic Nuclear Medicine Read Article »
By
| 13 minutes of readingRadioactive isotopes emit targeted radiation that effectively destroys cancer cells while minimising harm to healthy tissues.
Biological Principles Underpinning Targeted Radionuclide Therapy for Cancer Read Article »
By
| 10 minutes of readingYttrium-90 Citrate delivers targeted beta radiation, effectively treating synovial hypertrophy while minimising extra-articular radioactive escape risks.
By
| 11 minutes of readingZevalin therapy combines monoclonal antibody targeting with Yttrium-90 radiation to treat non-Hodgkin’s lymphoma effectively.
By
| 9 minutes of readingYttrium-90 FAPi-04 is a promising radiotherapeutic targeting fibroblast activation protein in cancer-associated fibroblasts effectively.
Yttrium-90 FAPi-04: A Novel Radiotherapeutic Targeting Fibroblast Activation Protein Read Article »
By
| 10 minutes of readingYttrium-90 Edotreotide delivers targeted beta radiation therapy to somatostatin receptor-positive neuroendocrine tumours with precision.
By
| 11 minutes of readingYttrium-90 DOTA-FF-21101 targets P-Cadherin in solid tumours, delivering beta radiation for precise cancer treatment.
By
| 9 minutes of readingYttrium-90 BetaGlue utilises polymerising microspheres to deliver precise brachytherapy, enhancing tumour control and improving patient outcomes.
Yttrium-90 BetaGlue: A Transforming Approach to Brachytherapy for Cancer Treatment Read Article »
By
| 11 minutes of readingYttrium-90 Besilesomab targets CD66-expressing cells, providing precise beta radiation therapy for systemic amyloid light chain amyloidosis.
By
| 11 minutes of readingYttrium-90 Anditixafortide targets CXCR4-expressing tumours, delivering therapeutic β– radiation precisely, improving treatment outcomes significantly.
By
| 4 minutes of readingRhenium-188 SSS/Lipiodol combines targeted delivery with beta radiation, offering hope for advanced hepatocellular carcinoma patients.
By
| 5 minutes of readingRhenium-SCT®: Innovative, precise, non-surgical therapy for non-melanoma skin cancer, ensuring safe and effective outcomes.
The Rhenium-SCT®: A Breakthrough in Non-Melanoma Skin Cancer Treatment Read Article »
By
| 8 minutes of readingRADIOPHARMACEUTICAL INNOVATION merges cutting-edge radiochemistry, targeted biology, and global clinical expertise, enhancing personalised treatments in oncology.
Radiopharmaceutical Innovation: An Overview for Targeted Therapy Read Article »
By
| 14 minutes of readingRhenium-188 HDD/Lipiodol therapy offers targeted radiopharmaceutical treatment for advanced hepatocellular carcinoma with portal vein thrombosis.
By
| 13 minutes of readingRhenium-188 P2045 is a peptide-based radiopharmaceutical targeting somatostatin receptors for treating neuroendocrine and pancreatic cancers.
By
| 13 minutes of readingRhenium-188 ImDendrim combines targeted nitro-imidazole ligands and dendrimers to deliver beta radiation to hypoxic tumours.
By
| 11 minutes of readingPancreatic cancer treatment has advanced significantly with the introduction of OncoSil brachytherapy for pancreatic cancer therapy.
By
| 5 minutes of readingPhosphorus-32 Colloidal Chromic Phosphate delivers precise beta radiation for treating malignant effusions and cystic tumours.
By
| 5 minutes of readingLutetium-177 Rituximab offers a targeted radiopharmaceutical solution, delivering beta radiation to CD20-positive cells, ensuring effective and precise lymphoma therapy.
Lutetium-177 Rituximab: A Novel Radiopharmaceutical for Non-Hodgkin Lymphoma (NHL) Read Article »
By
| 5 minutes of readingLutetium-177 PSMA-ALB-56 is an innovative treatment optimising prostate cancer therapy through targeted radiopharmaceutical advancements.
Lutetium-177 PSMA-ALB-56: A Promising Radiopharmaceutical for Prostate Cancer Therapy Read Article »
By
| 11 minutes of readingLutetium-177 MVT-1075 radioimmunotherapy targets pancreatic cancer by utilising CA19-9 specificity, sialyl-Lewis a binding, and precision radiation delivery.
Lutetium-177 MVT-1075: A Breakthrough in Pancreatic Cancer Radioimmunotherapy Read Article »
By
| 4 minutes of readingA novel radiolabelled drug, Lutetium-177 LNC1004, targets fibroblast activation protein, transforming cancer therapy through precision and innovation.
By
| 5 minutes of readingBetalutin combines the precision of CD37-targeting antibody Lilotomab with Lutetium-177, offering targeted and effective haematological cancer treatment.
Betalutin: A Revolutionary Therapeutic Pathway in Haematological Cancer Treatment Read Article »
By
| 5 minutes of readingTargeting Neurotensin Receptor-1 with Lutetium-177 IPN-01087 demonstrates promising precision therapy, delivering beta radiation for treating invasive cancers like ductal pancreatic adenocarcinoma.
Targeting Neurotensin Receptor-1: Lutetium-177 IPN-01087 in Oncology Read Article »
By
| 5 minutes of readingAdvancing prostate cancer treatment, Lutetium-177 HTK03170 and Gallium-68 HTK03149 enable targeted PSMA therapy, improving diagnosis and therapeutic outcomes.
By
| 4 minutes of readingRevolutionising cancer therapy, Lutetium-177 FAP-2286 offers precise diagnostics and targeted treatment, addressing solid tumours and fibrotic conditions effectively.
By
| 13 minutes of readingBremsstrahlung radiation occurs when high-energy electrons decelerate near atomic nuclei, emitting a continuous spectrum of electromagnetic photons.
Bremsstrahlung: Unveiling the Hidden Glow of Decelerating Electrons Read Article »
By
| 11 minutes of readingLutetium-177 DOTA-EB-FAPi revolutionises oncology by enhancing precision targeting of fibroblast activation protein, improving tumour uptake, and expanding therapeutic applications.
Lutetium-177 DOTA-EB-FAPi: Pioneering a New Era in Precision Oncology and Beyond Read Article »
By
| 9 minutes of readingRadiocarbon chemistry enables precise insights into carbon cycles, archaeological dating, drug development, and environmental impact analysis worldwide.
Radiocarbon Revolution: Tracing Chemistry Across Time and Applications Read Article »
